May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
May 14, 2020
Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
Jun 18, 2019
The BRAF kinase inhibitors market will register a CAGR of over 8% by 2023
May 16, 2019
Blood Test Can Measure Effectiveness of Treatments for Aggressive Skin Cancers
Jun 23, 2018
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer
May 16, 2018
BerGenBio to Present Interim Clinical and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO
Apr 30, 2018
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Dec 27, 2017
CStone files MEK inhibitor CS3006 for clinical trial approval in Australia
Dec 22, 2017
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Oct 30, 2017
Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim's BI 882370, a Novel and Potent RAF Inhibitor against Solid Tumors
Sep 10, 2017
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Jun 22, 2017
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)